Recent Advances in Screening for Mild Cognitive Impairment and Alzheimer Disease

Allan Anderson, MD, and Matthew Malone, DO, MBA

More than 6 million Americans\(^1\) are living with Alzheimer disease (AD), and that number is expected to reach 13 million by 2050.\(^1\) One in every 3 seniors dies with AD or another dementia, and AD kills more than breast cancer and prostate cancer combined.\(^1\) AD accounts for 60%–80% of all dementias,\(^2,3\) often overlapping with other pathologies including Lewy body dementia, vascular dementia, and hippocampal sclerosis. It is estimated that more than 11 million family caregivers\(^1\) provide around 16 billion hours in unpaid care, valued at nearly $272 billion.\(^1\) Total health care costs for people with Alzheimer and other dementias are expected to increase from $321 billion in 2022 to close to $1 trillion\(^1\) in 2050.

Within the last decade, scientists have discovered that certain biomarkers can be detected decades before the onset of AD symptoms,\(^9\) resulting in earlier diagnoses and interventions. Notable biomarkers include amyloid β (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau).\(^5\) Aβ42 in the brain signals the production of tau, which causes the neuronal damage and synaptic dysfunction underlying AD.\(^6\)

Early detection of these biomarkers can lead to early intervention and better patient outcomes. Through education, patients and families can gain a better understanding of the symptoms and changes that occur with AD and what the impact of the disease might be for them. With the time gained from faster diagnoses, patients with AD should discuss their treatment plan goals with their clinicians and weigh the risks and benefits of different treatment strategies together. Lifestyle interventions, financial planning, and seeking support services are additional benefits to an early diagnosis.\(^7\)
Differentiating between stages and types of dementia is an important step in optimizing patient outcomes, including the understanding that mild cognitive impairment (MCI) is not dementia.7 MCI is characterized by the patient or the patient's family or caregivers reporting changes in cognitive ability, without any major change in activities of daily living (although compensatory measures may be present), no explanation from psychiatric disorders, and objective evidence of cognitive impairment on a clinical examination.8

Several screening methods are available to differentiate among forms of dementia. The Mini Mental State Examination (MMSE) is the most common cognitive screening test. It is well-established and sensitive to memory disorders specifically. The MMSE consists of 11 questions, takes approximately 10 minutes to complete, and is easy to administer.9

The Montreal Cognitive Assessment (MoCA) is also becoming more widely adopted. Like the MMSE, MoCA takes around 10 minutes and consists of a 1-page document that uses a 30-point scale to assess memory, reasoning, and executive functioning.10 The MoCA can include the Memory Index Subscale (MIS), which calculates points for word recall in free recall, category prompts, and multiple choice. If total MoCA score is less than 20 and patients score less than 7 out of 15 on the MIS, the risk for progressing from MCI to AD increases by 60% in the next year.11 If the total MoCA score is >20 and the MIS is >7, then the risk for progressing from MCI to dementia is less than 35%. The MoCA is 90% sensitive and 87% specific for MCI.10,11

Other tests used to screen for dementia include the Saint Louis University Mental Status Exam (SLUMS), the General Practitioner Assessment of Cognition (GPCOG), and the Mini-Cog.12–14

It is important for clinicians to include patient history and physical and neurologic examinations in their assessments to rule out AD mimics, such as psychiatric illnesses, neurologic disorders, or metabolic changes. By capitalizing on the rapidly improving understanding of AD pathophysiology, clinicians should be better able to identify dementia, intervene appropriately, and ultimately improve patient outcomes.

Published online: December 26, 2022.

Unlabeled and investigational usage: The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses. Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.

REFERENCES
1. Which of the following biomarkers plays a key role in the pathogenesis of AD and serves as a biomarker for diagnosis?
   a. Phosphorylated neurofilament heavy chain (pNFH)
   b. Aquaporin-4 (AQP-4)
   c. α-synuclein (aS)
   d. Aβ42

2. On the Montreal Cognitive Assessment, a total score _____ is associated with a 60% increased risk in progressing from mild cognitive impairment to AD within 1 year.
   a. Less than 18
   b. Less than 20
   c. Less than 22
   d. Less than 24